Compare MINISO Group Holding Ltd (MNSO) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MINISO Group Holding Ltd vs Novavax Inc — how do they compare? MINISO Group Holding Ltd trades at $9.6 (market cap $2.65B), while Novavax Inc trades at $12.75 (market cap $1.82B). The key difference: MINISO Group Holding Ltd is the larger of the two by market cap, and MINISO Group Holding Ltd pays a 7.34% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold MINISO Group Holding Ltd for 25 Days and Novavax Inc for 59 Days on average.
| MNSO | NVAX | |
|---|---|---|
Market Cap | $2.65B | $1.82B |
Volume | 747,763 | 6,198,505 |
Sector | Consumer Cyclical | Health |
52-Week High | $22.75 | $12.75 |
52-Week Low | $8.60 | $6.22 |
Typical Hold Time | 25 Days | 59 Days |
Enterprise Value | $3.52B | $1.39B |
Dividend Yield | 7.34% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MNSO trades at $9.07, up 1.45% with mixed technical signals showing bearish moving averages but neutral oscillators. Fundamentally, the company reported strong revenue growth to $21.44B in 2025 with 5.35% net margin, though recent quarterly earnings show volatility with three misses and one beat. Valuation appears reasonable with P/E of 14.76 and P/S of 0.79. Recent CFO share purchases and positive domestic performance provide support amid overseas margin pressures.
The stock presents a value opportunity with attractive valuation multiples and solid Chinese market growth, but faces execution risks from international expansion and earnings inconsistency. Analyst consensus leans bullish (60% buy ratings) despite recent price weakness, suggesting potential upside if management can stabilize overseas operations and maintain domestic momentum.
Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and a strong buy consensus from analysts (73.9% buy ratings). The company reported a net income of $440.3M in 2025, a significant turnaround from prior losses, though 2026 projections show a return to negative margins. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.
The outlook is mixed: near-term catalysts include partnership-driven growth and vaccine approvals, but persistent cash burn and projected 2026 losses pose risks. Investor sentiment is buoyed by recent earnings beats and strategic shifts, yet execution on profitability remains critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MINISO Group Holding Ltd
MINISO Group Holding Ltd is a global lifestyle product retailer known for its aesthetically pleasing, high-quality, and low-cost goods. The company operates a network of branded stores worldwide, offering a diverse range of merchandise, including household goods, cosmetics, toys, and digital accessories. MINISO's business model emphasizes rapid product iteration, efficient supply chain management, and a joint venture and franchise partner network to facilitate its global expansion.
Read more on MNSO →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
